Phase 2 Multi-Center Study Of Tazemetostat (Epz-6438), An Inhibitor Of Enhancer Of Zeste-Homolog 2 (Ezh2), In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma (Nhl).
JOURNAL OF CLINICAL ONCOLOGY(2016)
Abstract
TPS7582Background: The histone transferase EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) responsible for methylating lysine 27 of histone H3, a mark associated with repr...
MoreTranslated text
Key words
ezh2,tazemetostat,inhibitor,enhancer,multi-center,zeste-homolog,b-cell,non-hodgkin
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined